Literature DB >> 7682457

Antibodies to myelin basic protein in children with autistic behavior.

V K Singh1, R P Warren, J D Odell, W L Warren, P Cole.   

Abstract

Based on a possible pathological relationship of autoimmunity to autism, antibodies reactive with myelin basic protein (anti-MBP) were investigated in the sera of autistic children. Using a screening serum dilution of 1:400 in the protein-immunoblotting technique, approximately 58% (19 of 33) sera of autistic children (< or = 10 years of age) were found to be positive for anti-MBP. This result in autistics was significantly (p < or = .0001) different from the controls (8 of 88 or only 9% positive), which included age-matched children with normal health, idiopathic mental retardation (MR) and Down syndrome (DS), and normal adults of 20 to 40 years of age. Since autism is a syndrome of unknown etiology, it is possible that anti-MBP antibodies are associated with the development of autistic behavior.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7682457     DOI: 10.1006/brbi.1993.1010

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  58 in total

1.  Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism.

Authors:  G DelGiudice-Asch; L Simon; J Schmeidler; C Cunningham-Rundles; E Hollander
Journal:  J Autism Dev Disord       Date:  1999-04

2.  Exclusion of linkage to the HLA region in ninety multiplex sibships with autism.

Authors:  T Rogers; L Kalaydjieva; J Hallmayer; P B Petersen; P Nicholas; C Pingree; W M McMahon; D Spiker; L Lotspeich; H Kraemer; P McCague; S Dimiceli; N Nouri; T Peachy; J Yang; D Hinds; N Risch; R M Myers
Journal:  J Autism Dev Disord       Date:  1999-06

3.  Immunological treatments for autism.

Authors:  S Gupta
Journal:  J Autism Dev Disord       Date:  2000-10

Review 4.  Immune dysfunction in autism: a pathway to treatment.

Authors:  Milo Careaga; Judy Van de Water; Paul Ashwood
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

Review 5.  Immune therapy in autism: historical experience and future directions with immunomodulatory therapy.

Authors:  Michael G Chez; Natalie Guido-Estrada
Journal:  Neurotherapeutics       Date:  2010-07       Impact factor: 7.620

6.  Macrophage migration inhibitory factor and autism spectrum disorders.

Authors:  Elena L Grigorenko; Summer S Han; Carolyn M Yrigollen; Lin Leng; Yuka Mizue; George M Anderson; Erik J Mulder; Annelies de Bildt; Ruud B Minderaa; Fred R Volkmar; Joseph T Chang; Richard Bucala
Journal:  Pediatrics       Date:  2008-08       Impact factor: 7.124

Review 7.  The role of immune dysfunction in the pathophysiology of autism.

Authors:  Charity Onore; Milo Careaga; Paul Ashwood
Journal:  Brain Behav Immun       Date:  2011-08-28       Impact factor: 7.217

8.  How relevant are GFAP autoantibodies in autism and Tourette Syndrome?

Authors:  Nikki J Kirkman; Jane E Libbey; Thayne L Sweeten; Hilary H Coon; Judith N Miller; Edward K Stevenson; Janet E Lainhart; William M McMahon; Robert S Fujinami
Journal:  J Autism Dev Disord       Date:  2007-06-20

9.  Family analysis of immunoglobulin classes and subclasses in children with autistic disorder.

Authors:  Mirko Spiroski; Vladimir Trajkovski; Dejan Trajkov; Aleksandar Petlichkovski; Olivija Efinska-Mladenovska; Slavica Hristomanova; Eli Djulejic; Meri Paneva; Jadranka Bozhikov
Journal:  Bosn J Basic Med Sci       Date:  2009-11       Impact factor: 3.363

10.  Pathogenesis of autism: a patchwork of genetic causes.

Authors:  Elena L Grigorenko
Journal:  Future Neurol       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.